100 mg AP1189

DRUG2 trials

Sponsors

SynAct Pharma Aps

Conditions

Nephrotic Syndrome Due to Idiopathic Membranous NephropathyRheumatoid ArthritisSevere Proteinuria Due to Idiopathic Membranous Nephropathy

Phase 2

A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria

RecruitingNCT04456816

SynAct Pharma ApsNephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy

Start: 2020-08-31End: 2026-06-30Target: 23Updated: 2026-03-06

A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment

CompletedNCT05516979

SynAct Pharma ApsRheumatoid Arthritis

Start: 2022-09-26End: 2023-07-20Updated: 2023-11-07